grant

DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT

Organization BATTELLE CENTERS/PUB HLTH RES & EVALUATNLocation COLUMBUS, UNITED STATESPosted 7 Feb 2023Deadline 6 Feb 2028
NIHUS FederalResearch GrantFY2023AntibodiesAntibody TherapyBiologic ProductsBiological AgentBiological ProductsCharacteristicsClinical TrialsCooperative AgreementsDevelopmentDucheneDuchenneDuchenne muscular dystrophyDuchenne-Griesinger syndromeELISAEllis-van Creveld (EvC) syndromeEnzyme-Linked Immunosorbent AssayEvaluationFundingGoalsIn VitroLeadNINDSNational Institute of Neurological Diseases and StrokeNational Institute of Neurological Disorders and StrokeNational Institutes of HealthNervous System DiseasesNeurologic DisordersNeurological DisordersPb elementPseudohypertrophic Muscular DystrophyU-Series Cooperative AgreementsUnited States National Institutes of HealthX-linked dilated cardiomyopathyX-linked muscular dystrophyX-linked recessive muscular dystrophyantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentbenign X-linked recessive muscular dystrophybiologicsbiopharmaceuticalbiotherapeutic agentchildhood pseudohypertrophic muscular dystrophyclassic X-linked recessive muscular dystrophyclinical candidatedevelop therapydevelopmentalenzyme linked immunoassayheavy metal Pbheavy metal leadin vivointervention developmentlead optimizationmanufacturemild X-linked recessive muscular dystrophynervous system disorderneurological diseasepre-clinical studypreclinical studyprogressive muscular dystrophy of childhoodpseudohypertrophic adult muscular dystrophypseudohypertrophic muscular paralysistherapy developmenttreatment development
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

The National Institute of Neurological Disorders and Stroke (NINDS), via its Blueprint (BPNBiologics)
network, is funding a cooperative agreement for the development of an antibody

for treatment of Duchenne’s muscular

dystrophy (DMD). The goals of the BPN-Biologics cooperative agreement are to optimize the

lead antibody, evaluate short-term in…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →